Menu
← Oncology Approval Tracker
FDA DECISION ·
Amtagvi
lifileucel · Iovance Biotherapeutics
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with unresectable or metastatic melanoma after a PD-1 blocker and, if BRAF V600 positive, a BRAF inhibitor with or without a MEK inhibitor.
LAMPGEN ANALYSIS
Why it matters
This tumor-infiltrating lymphocyte therapy brings an individualized cell product to the post-checkpoint melanoma setting.
What research teams should watch
Coordinate tumor procurement, manufacturing, lymphodepletion and post-infusion interleukin-2 support across teams.
PRIMARY RECORDS